December 8, 2021
Chugai Pharmaceutical said on December 7 that a key European advisory panel recommended approval of its humanized anti-human IL-6 receptor monoclonal antibody tocilizumab, known with the brand names of Actemra/RoActemra, for the treatment of severe COVID-19. The European Medicines Agency’s...read more